JP2008530011A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008530011A5 JP2008530011A5 JP2007554205A JP2007554205A JP2008530011A5 JP 2008530011 A5 JP2008530011 A5 JP 2008530011A5 JP 2007554205 A JP2007554205 A JP 2007554205A JP 2007554205 A JP2007554205 A JP 2007554205A JP 2008530011 A5 JP2008530011 A5 JP 2008530011A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pyridin
- pyrazol
- alkyl
- oxime
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 77
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 63
- 125000000623 heterocyclic group Chemical group 0.000 claims 49
- 125000000217 alkyl group Chemical group 0.000 claims 45
- 125000003118 aryl group Chemical group 0.000 claims 32
- -1 carbocycle Chemical group 0.000 claims 30
- 125000004452 carbocyclyl group Chemical group 0.000 claims 27
- 125000003342 alkenyl group Chemical group 0.000 claims 18
- 125000000304 alkynyl group Chemical group 0.000 claims 16
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 13
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 125000004429 atom Chemical group 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 150000003951 lactams Chemical class 0.000 claims 7
- 150000002596 lactones Chemical class 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000000069 prophylactic effect Effects 0.000 claims 4
- 125000006239 protecting group Chemical group 0.000 claims 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 3
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 3
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 claims 2
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- JQGPBDSMTHZOMO-UHFFFAOYSA-N OBO.C=1C=NNC=1 Chemical class OBO.C=1C=NNC=1 JQGPBDSMTHZOMO-UHFFFAOYSA-N 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 235000010290 biphenyl Nutrition 0.000 claims 2
- 239000004305 biphenyl Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims 1
- IZQZVLNYVZCOPX-UHFFFAOYSA-N 2-[2-[4-(1-hydroxyimino-2,3-dihydroinden-5-yl)-3-pyridin-4-ylpyrazol-1-yl]ethylamino]ethanol Chemical compound N=1N(CCNCCO)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 IZQZVLNYVZCOPX-UHFFFAOYSA-N 0.000 claims 1
- FKWQBUGNQFJRGV-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-yl)-3-pyridin-4-ylpyrazol-1-yl]ethanol Chemical compound N=1N(CCO)C=C(C=2C=C3OCOC3=CC=2)C=1C1=CC=NC=C1 FKWQBUGNQFJRGV-UHFFFAOYSA-N 0.000 claims 1
- MJESHTQDIHRJJJ-UHFFFAOYSA-N 2-[4-(1-amino-2,3-dihydro-1h-inden-5-yl)-3-pyridin-4-ylpyrazol-1-yl]ethanol Chemical compound C=1C=C2C(N)CCC2=CC=1C1=CN(CCO)N=C1C1=CC=NC=C1 MJESHTQDIHRJJJ-UHFFFAOYSA-N 0.000 claims 1
- IEPBUTPKELRFKK-UHFFFAOYSA-N 2-[4-(1-amino-2,3-dihydro-1h-inden-5-yl)-5-pyridin-4-ylpyrazol-1-yl]ethanol Chemical compound C=1C=C2C(N)CCC2=CC=1C=1C=NN(CCO)C=1C1=CC=NC=C1 IEPBUTPKELRFKK-UHFFFAOYSA-N 0.000 claims 1
- PKGNJPQGDHTVGY-UHFFFAOYSA-N 2-[4-(1-hydroxyimino-2,3-dihydroinden-5-yl)-3-pyridin-4-ylpyrazol-1-yl]pyridine-3-carbonitrile Chemical compound C=1C=C2C(=NO)CCC2=CC=1C1=CN(C=2C(=CC=CN=2)C#N)N=C1C1=CC=NC=C1 PKGNJPQGDHTVGY-UHFFFAOYSA-N 0.000 claims 1
- SQFQKKPNPXONBG-UHFFFAOYSA-N 2-[4-(1-hydroxyimino-2,3-dihydroinden-5-yl)-5-pyridin-4-ylpyrazol-1-yl]ethanol Chemical compound OCCN1N=CC(C=2C=C3CCC(C3=CC=2)=NO)=C1C1=CC=NC=C1 SQFQKKPNPXONBG-UHFFFAOYSA-N 0.000 claims 1
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 claims 1
- VATRAMGKPXJFAV-UHFFFAOYSA-N 3-[4-(1-hydroxyimino-2,3-dihydroinden-5-yl)-3-pyridin-4-ylpyrazol-1-yl]propane-1,2-diol Chemical compound N=1N(CC(O)CO)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 VATRAMGKPXJFAV-UHFFFAOYSA-N 0.000 claims 1
- RCBZCSONTXNSHW-UHFFFAOYSA-N 4-[1-piperidin-4-yl-4-[6-(1h-pyrazol-5-yl)-2,4,5,6-tetrahydro-1h-inden-5-yl]pyrazol-3-yl]pyridine Chemical compound C1C2=CCCC2=CC(C2=NNC=C2)C1C1=CN(C2CCNCC2)N=C1C1=CC=NC=C1 RCBZCSONTXNSHW-UHFFFAOYSA-N 0.000 claims 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
- RICPRHNLFHUQIT-UHFFFAOYSA-N 5-(1-methyl-3-pyridin-4-ylpyrazol-4-yl)-1,3-dihydroindol-2-one Chemical compound N=1N(C)C=C(C=2C=C3CC(=O)NC3=CC=2)C=1C1=CC=NC=C1 RICPRHNLFHUQIT-UHFFFAOYSA-N 0.000 claims 1
- NWAIAPGJHCMCJQ-UHFFFAOYSA-N 5-(1-methyl-3-pyridin-4-ylpyrazol-4-yl)-2,3-dihydroinden-1-one Chemical compound N=1N(C)C=C(C=2C=C3CCC(=O)C3=CC=2)C=1C1=CC=NC=C1 NWAIAPGJHCMCJQ-UHFFFAOYSA-N 0.000 claims 1
- XIWGEASMKDCYFJ-UHFFFAOYSA-N 5-(5-pyridin-4-yl-1h-pyrazol-4-yl)-2,3-dihydroinden-1-one Chemical compound C=1C=C2C(=O)CCC2=CC=1C1=CNN=C1C1=CC=NC=C1 XIWGEASMKDCYFJ-UHFFFAOYSA-N 0.000 claims 1
- CACKWIAQZGWUDK-UHFFFAOYSA-N 5-[1-(1-methylpiperidin-4-yl)-3-pyridin-4-ylpyrazol-4-yl]-3h-isoindol-1-amine Chemical compound C1CN(C)CCC1N1N=C(C=2C=CN=CC=2)C(C=2C=C3CNC(=N)C3=CC=2)=C1 CACKWIAQZGWUDK-UHFFFAOYSA-N 0.000 claims 1
- DEZZLWQELQORIU-UHFFFAOYSA-N 5-[1-(2-hydroxyethyl)-3-pyridin-4-yl-4-pyrazolyl]-2,3-dihydroinden-1-one oxime Chemical compound N=1N(CCO)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 DEZZLWQELQORIU-UHFFFAOYSA-N 0.000 claims 1
- MGGQMXLSPADSGN-UHFFFAOYSA-N 5-[1-(2-hydroxyethyl)-3-pyridin-4-ylpyrazol-4-yl]-1,3-dihydroindol-2-one Chemical compound N=1N(CCO)C=C(C=2C=C3CC(=O)NC3=CC=2)C=1C1=CC=NC=C1 MGGQMXLSPADSGN-UHFFFAOYSA-N 0.000 claims 1
- UMUDEJRSKACPSS-UHFFFAOYSA-N 5-[1-(2-hydroxyethyl)-3-pyridin-4-ylpyrazol-4-yl]-1h-quinazolin-4-one Chemical compound N=1N(CCO)C=C(C=2C=3C(=O)NC=NC=3C=CC=2)C=1C1=CC=NC=C1 UMUDEJRSKACPSS-UHFFFAOYSA-N 0.000 claims 1
- XRDGWIKOQYEFOL-UHFFFAOYSA-N 5-[1-(2-hydroxyethyl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-one Chemical compound N=1N(CCO)C=C(C=2C=C3CCC(=O)C3=CC=2)C=1C1=CC=NC=C1 XRDGWIKOQYEFOL-UHFFFAOYSA-N 0.000 claims 1
- UIBKJNFSKLXWTK-UHFFFAOYSA-N 5-[1-(2-hydroxyethyl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydrophthalazine-1,4-dione Chemical compound N=1N(CCO)C=C(C=2C3=C(C(NNC3=O)=O)C=CC=2)C=1C1=CC=NC=C1 UIBKJNFSKLXWTK-UHFFFAOYSA-N 0.000 claims 1
- VFWDUSGVXPKDHF-UHFFFAOYSA-N 5-[1-(2-hydroxyethyl)-3-pyridin-4-ylpyrazol-4-yl]-2-(2-methoxyethyl)isoindole-1,3-dione Chemical compound C1=C2C(=O)N(CCOC)C(=O)C2=CC=C1C1=CN(CCO)N=C1C1=CC=NC=C1 VFWDUSGVXPKDHF-UHFFFAOYSA-N 0.000 claims 1
- YNEHWTFXTODKTQ-UHFFFAOYSA-N 5-[1-(2-hydroxyethyl)-3-pyridin-4-ylpyrazol-4-yl]-2h-isoquinolin-1-one Chemical compound N=1N(CCO)C=C(C=2C3=CC=NC(O)=C3C=CC=2)C=1C1=CC=NC=C1 YNEHWTFXTODKTQ-UHFFFAOYSA-N 0.000 claims 1
- SZOSXNZCMNUXFR-UHFFFAOYSA-N 5-[1-[2-(4-methylpiperazin-1-yl)ethyl]-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydro-1h-inden-1-amine Chemical compound C1CN(C)CCN1CCN1N=C(C=2C=CN=CC=2)C(C=2C=C3CCC(N)C3=CC=2)=C1 SZOSXNZCMNUXFR-UHFFFAOYSA-N 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- HXGBUKKPDSRQTR-UHFFFAOYSA-N 6-(1-methyl-3-pyridin-4-ylpyrazol-4-yl)naphthalen-1-ol Chemical compound N=1N(C)C=C(C=2C=C3C=CC=C(O)C3=CC=2)C=1C1=CC=NC=C1 HXGBUKKPDSRQTR-UHFFFAOYSA-N 0.000 claims 1
- RILYHIWSBNWFIQ-GMAHTHKFSA-N 6-[1-[(1s,2s)-2-hydroxycyclohexyl]-3-pyridin-4-ylpyrazol-4-yl]naphthalen-1-ol Chemical compound O[C@H]1CCCC[C@@H]1N1N=C(C=2C=CN=CC=2)C(C=2C=C3C=CC=C(O)C3=CC=2)=C1 RILYHIWSBNWFIQ-GMAHTHKFSA-N 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- RMTGMEXYMKRUSY-UHFFFAOYSA-N N-[5-(1-methyl-5-pyridin-4-ylpyrazol-4-yl)-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound CN1N=CC(C=2C=C3CCC(C3=CC=2)=NO)=C1C1=CC=NC=C1 RMTGMEXYMKRUSY-UHFFFAOYSA-N 0.000 claims 1
- HNYYFWGWLSEHQF-UHFFFAOYSA-N N-[5-(5-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C1=CNN=C1C1=CC=NC=C1 HNYYFWGWLSEHQF-UHFFFAOYSA-N 0.000 claims 1
- BFXCZPXEDHBYBJ-UHFFFAOYSA-N N-[5-[1-(1-methylpiperidin-4-yl)-3-pyridin-4-ylpyrazol-4-yl]-3H-isoindol-1-yl]hydroxylamine Chemical compound C1CN(C)CCC1N1N=C(C=2C=CN=CC=2)C(C=2C=C3CNC(/C3=CC=2)=N\O)=C1 BFXCZPXEDHBYBJ-UHFFFAOYSA-N 0.000 claims 1
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 1
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 208000015322 bone marrow disease Diseases 0.000 claims 1
- 201000000220 brain stem cancer Diseases 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- RXOAUTDNEHGRQR-UHFFFAOYSA-N chembl524643 Chemical compound N=1N(C)C=C(C=2C=C3CNC(/C3=CC=2)=N\O)C=1C1=CC=NC=C1 RXOAUTDNEHGRQR-UHFFFAOYSA-N 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 210000002768 hair cell Anatomy 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 208000033065 inborn errors of immunity Diseases 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 201000011061 large intestine cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000000088 lip Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- GBESZLUYUDEPLT-UHFFFAOYSA-N n-[3-[4-(1-hydroxyimino-2,3-dihydroinden-5-yl)-3-pyridin-4-ylpyrazol-1-yl]propyl]-2-methoxyacetamide Chemical compound N=1N(CCCNC(=O)COC)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 GBESZLUYUDEPLT-UHFFFAOYSA-N 0.000 claims 1
- UMEKRJBKRPLHKL-UHFFFAOYSA-N n-[5-(1-cyclopentyl-3-pyridin-4-ylpyrazol-4-yl)-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C1=CN(C2CCCC2)N=C1C1=CC=NC=C1 UMEKRJBKRPLHKL-UHFFFAOYSA-N 0.000 claims 1
- ZDPNNLPNJKVPAJ-UHFFFAOYSA-N n-[5-(1-methyl-3-pyridin-4-ylpyrazol-4-yl)-1-benzofuran-3-ylidene]hydroxylamine Chemical compound N=1N(C)C=C(C=2C=C3C(=NO)COC3=CC=2)C=1C1=CC=NC=C1 ZDPNNLPNJKVPAJ-UHFFFAOYSA-N 0.000 claims 1
- PALWZOUPWYHIBZ-UHFFFAOYSA-N n-[5-(1-methyl-3-pyridin-4-ylpyrazol-4-yl)-2,3-dihydrochromen-4-ylidene]hydroxylamine Chemical compound N=1N(C)C=C(C=2C=3C(=NO)CCOC=3C=CC=2)C=1C1=CC=NC=C1 PALWZOUPWYHIBZ-UHFFFAOYSA-N 0.000 claims 1
- QULKREMAADOCHU-UHFFFAOYSA-N n-[5-(1-methyl-3-pyridin-4-ylpyrazol-4-yl)-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound N=1N(C)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 QULKREMAADOCHU-UHFFFAOYSA-N 0.000 claims 1
- KWEFZSZCLBHIEQ-UHFFFAOYSA-N n-[5-(1-piperidin-4-yl-3-pyridin-4-ylpyrazol-4-yl)-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C1=CN(C2CCNCC2)N=C1C1=CC=NC=C1 KWEFZSZCLBHIEQ-UHFFFAOYSA-N 0.000 claims 1
- BHLMLSGRHJUIKL-UHFFFAOYSA-N n-[5-(2-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-3-yl)-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C(=C1N=CC=CN1N=1)C=1C1=CC=NC=C1 BHLMLSGRHJUIKL-UHFFFAOYSA-N 0.000 claims 1
- DFDQKBZNHIAFHM-UHFFFAOYSA-N n-[5-(3-pyridin-4-yl-1-pyrrolidin-3-ylpyrazol-4-yl)-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C1=CN(C2CNCC2)N=C1C1=CC=NC=C1 DFDQKBZNHIAFHM-UHFFFAOYSA-N 0.000 claims 1
- OJMSXFJCMHLRGA-UHFFFAOYSA-N n-[5-[1-(2-aminoethyl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound N=1N(CCN)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 OJMSXFJCMHLRGA-UHFFFAOYSA-N 0.000 claims 1
- DTGWIQVKISSKJV-UHFFFAOYSA-N n-[5-[1-(2-piperidin-1-ylethyl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C(C(=N1)C=2C=CN=CC=2)=CN1CCN1CCCCC1 DTGWIQVKISSKJV-UHFFFAOYSA-N 0.000 claims 1
- XBYGGIAFXHDSJP-UHFFFAOYSA-N n-[5-[1-(3-aminopropyl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound N=1N(CCCN)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 XBYGGIAFXHDSJP-UHFFFAOYSA-N 0.000 claims 1
- RGMKIWCFVYETDM-UHFFFAOYSA-N n-[5-[1-(4-aminobutyl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound N=1N(CCCCN)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 RGMKIWCFVYETDM-UHFFFAOYSA-N 0.000 claims 1
- QPROAMYIMIWMOV-UHFFFAOYSA-N n-[5-[1-(4-methylpiperidin-1-yl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C1CC(C)CCN1N1N=C(C=2C=CN=CC=2)C(C=2C=C3CCC(C3=CC=2)=NO)=C1 QPROAMYIMIWMOV-UHFFFAOYSA-N 0.000 claims 1
- RZCDDUDKDKUXLC-UHFFFAOYSA-N n-[5-[1-(oxan-4-yl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C1=CN(C2CCOCC2)N=C1C1=CC=NC=C1 RZCDDUDKDKUXLC-UHFFFAOYSA-N 0.000 claims 1
- NOBRYXWIIOWOPC-QGZVFWFLSA-N n-[5-[1-[(3r)-oxolan-3-yl]-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C1=CN([C@H]2COCC2)N=C1C1=CC=NC=C1 NOBRYXWIIOWOPC-QGZVFWFLSA-N 0.000 claims 1
- AVUPTZCSKVHLFN-UHFFFAOYSA-N n-[5-[1-[2-(4-methylpiperazin-1-yl)ethyl]-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C1CN(C)CCN1CCN1N=C(C=2C=CN=CC=2)C(C=2C=C3CCC(C3=CC=2)=NO)=C1 AVUPTZCSKVHLFN-UHFFFAOYSA-N 0.000 claims 1
- BNZFFQFIDFWDFA-UHFFFAOYSA-N n-[5-[1-[3-(aminomethyl)pyridin-2-yl]-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound NCC1=CC=CN=C1N1N=C(C=2C=CN=CC=2)C(C=2C=C3CCC(C3=CC=2)=NO)=C1 BNZFFQFIDFWDFA-UHFFFAOYSA-N 0.000 claims 1
- CYJGATFIVAHKTM-UHFFFAOYSA-N n-[5-[1-[4-(aminomethyl)phenyl]-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C1=CC(CN)=CC=C1N1N=C(C=2C=CN=CC=2)C(C=2C=C3CCC(C3=CC=2)=NO)=C1 CYJGATFIVAHKTM-UHFFFAOYSA-N 0.000 claims 1
- ZNRRHRJCCXLLCS-UHFFFAOYSA-N n-[5-[1-[5-(aminomethyl)pyridin-2-yl]-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound N1=CC(CN)=CC=C1N1N=C(C=2C=CN=CC=2)C(C=2C=C3CCC(C3=CC=2)=NO)=C1 ZNRRHRJCCXLLCS-UHFFFAOYSA-N 0.000 claims 1
- WWZAMNZDVNQWRK-UHFFFAOYSA-N n-[6-[4-(1-hydroxyimino-2,3-dihydroinden-5-yl)-3-pyridin-4-ylpyrazol-1-yl]pyridin-3-yl]acetamide Chemical compound N1=CC(NC(=O)C)=CC=C1N1N=C(C=2C=CN=CC=2)C(C=2C=C3CCC(C3=CC=2)=NO)=C1 WWZAMNZDVNQWRK-UHFFFAOYSA-N 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 231100000189 neurotoxic Toxicity 0.000 claims 1
- 230000002887 neurotoxic effect Effects 0.000 claims 1
- 239000003900 neurotrophic factor Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 150000002923 oximes Chemical class 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims 1
- 125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims 1
- 102000009929 raf Kinases Human genes 0.000 claims 1
- 108010077182 raf Kinases Proteins 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- GEQCVKWGYURITF-UHFFFAOYSA-N tert-butyl n-[5-[1-(2-hydroxyethyl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydro-1h-inden-1-yl]carbamate Chemical compound C=1C=C2C(NC(=O)OC(C)(C)C)CCC2=CC=1C1=CN(CCO)N=C1C1=CC=NC=C1 GEQCVKWGYURITF-UHFFFAOYSA-N 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000002105 tongue Anatomy 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 125000004665 trialkylsilyl group Chemical group 0.000 claims 1
- 125000005039 triarylmethyl group Chemical group 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 0 *C1C(*)=C(c2c(*)[n](*)nc2*)C(*)=C(CN2*)[C@]1C2=N* Chemical compound *C1C(*)=C(c2c(*)[n](*)nc2*)C(*)=C(CN2*)[C@]1C2=N* 0.000 description 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65005005P | 2005-02-04 | 2005-02-04 | |
| PCT/US2006/003654 WO2006084015A2 (en) | 2005-02-04 | 2006-02-02 | Raf inhibitor compounds and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008530011A JP2008530011A (ja) | 2008-08-07 |
| JP2008530011A5 true JP2008530011A5 (cg-RX-API-DMAC10.html) | 2009-02-26 |
Family
ID=36571626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007554205A Pending JP2008530011A (ja) | 2005-02-04 | 2006-02-02 | Ｒａｆインヒビター化合物および方法 |
Country Status (18)
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007305016B2 (en) | 2006-10-02 | 2011-11-03 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| CN101611016B (zh) * | 2006-10-17 | 2012-01-25 | 斯蒂菲尔实验室公司 | 他拉罗唑代谢物 |
| JP2010540451A (ja) * | 2007-09-20 | 2010-12-24 | ワイス・エルエルシー | ピラゾロ［５，１−ｃ］［１，２，４］トリアジン、その調製法および使用法 |
| CA2716947A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
| AR072657A1 (es) * | 2008-02-29 | 2010-09-15 | Genentech Inc | Compuestos inhibidores de raf y metodos para su uso |
| WO2009111260A1 (en) * | 2008-02-29 | 2009-09-11 | Wyeth | Phenylsulfonamide-substituted, pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof |
| US20110003859A1 (en) * | 2008-02-29 | 2011-01-06 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| WO2009111278A2 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| WO2009108827A1 (en) * | 2008-02-29 | 2009-09-03 | Wyeth | Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof |
| JP2009286773A (ja) * | 2008-03-14 | 2009-12-10 | Bayer Cropscience Ag | 殺虫性縮環式アリール類 |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| JP2011523646A (ja) | 2008-05-21 | 2011-08-18 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのリン誘導体 |
| EP2381777A4 (en) * | 2008-12-12 | 2012-08-08 | Ariad Pharma Inc | AZAINDOL DERIVATIVES AS KINASEHEMMER |
| US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
| SG178854A1 (en) | 2009-08-28 | 2012-04-27 | Array Biopharma Inc | Raf inhibitor compounds and methods of use thereof |
| EP2470538A1 (en) | 2009-08-28 | 2012-07-04 | Array Biopharma, Inc. | Raf inhibitor compounds and methods of use thereof |
| CN102858754A (zh) | 2009-08-28 | 2013-01-02 | 阵列生物制药公司 | Raf抑制剂化合物及其使用方法 |
| US20120157452A1 (en) | 2009-08-28 | 2012-06-21 | Genentech, Inc. | 1h-pyrazolo[3,4-b] pyridine compounds for inhibiting raf kinase |
| SG178853A1 (en) | 2009-08-28 | 2012-04-27 | Array Biopharma Inc | Raf inhibitor compounds and methods of use thereof |
| WO2011025965A1 (en) | 2009-08-28 | 2011-03-03 | Genentech, Inc. | Raf inhibitor compounds and methods of use thereof |
| WO2011051478A1 (en) * | 2009-10-30 | 2011-05-05 | Domain Therapeutics | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| EP2937345B1 (en) | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| PH12012501361A1 (en) | 2009-12-31 | 2012-10-22 | Centro Nac De Investigaciones Oncologicas Cnio | Tricyclic compounds for use as kinase inhibitors |
| US20120122928A1 (en) | 2010-08-11 | 2012-05-17 | Bayer Cropscience Ag | Heteroarylpiperidine and -Piperazine Derivatives as Fungicides |
| US8759527B2 (en) | 2010-08-25 | 2014-06-24 | Bayer Cropscience Ag | Heteroarylpiperidine and -piperazine derivatives as fungicides |
| EP2423210A1 (de) | 2010-08-25 | 2012-02-29 | Bayer CropScience AG | Heteroarylpiperidin- und -piperazinderivate als Fungizide |
| EP2632922B1 (de) | 2010-10-27 | 2019-02-27 | Bayer CropScience Aktiengesellschaft | Heteroarylpiperidin und -piperazinderivate als fungizide |
| CA2824028A1 (en) | 2011-01-06 | 2012-07-12 | Beta Pharma Canada Inc. | Novel ureas for the treatment and prevention of cancer |
| WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
| WO2012104273A1 (de) | 2011-02-01 | 2012-08-09 | Bayer Cropscience Ag | Heteroarylpiperidin und -piperazinderivate als fungizide |
| WO2012145503A1 (en) | 2011-04-21 | 2012-10-26 | Novartis Ag | Pharmaceutical combinations |
| AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| AU2012312515A1 (en) | 2011-09-19 | 2014-03-13 | Genentech, Inc. | Combination treatments comprising c-met antagonists and B-raf antagonists |
| JP6106685B2 (ja) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤 |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| ES2695233T3 (es) | 2011-12-27 | 2019-01-02 | Bayer Cropscience Ag | Derivados de isoxazol |
| DK2797888T3 (en) * | 2011-12-31 | 2016-09-19 | Beigene Ltd | Fused tricyclic compounds as RAF kinase inhibitors |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| DK2884979T3 (da) | 2012-08-17 | 2019-09-02 | Hoffmann La Roche | Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
| WO2014128235A1 (en) | 2013-02-22 | 2014-08-28 | F. Hoffmann-La Roche Ag | Methods of treating cancer and preventing drug resistance |
| JO3383B1 (ar) * | 2013-03-14 | 2019-03-13 | Lilly Co Eli | مثبطات cdc7 |
| HK1214533A1 (zh) | 2013-03-15 | 2016-07-29 | 基因泰克公司 | 治疗癌症和预防癌症耐药性的方法 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| WO2014206344A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| US9629851B2 (en) | 2013-09-20 | 2017-04-25 | Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis | ROCK in combination with MAPK pathway |
| WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
| WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| AU2014337044A1 (en) | 2013-10-18 | 2016-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
| EP3122900A1 (en) | 2014-03-24 | 2017-02-01 | F. Hoffmann-La Roche AG | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
| US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
| WO2015191986A1 (en) | 2014-06-13 | 2015-12-17 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
| US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| BR112017000672A2 (pt) | 2014-07-15 | 2017-11-14 | Genentech Inc | composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek |
| KR102524920B1 (ko) | 2014-07-22 | 2023-04-25 | 아폴로믹스 인코포레이티드 | 항-pd-1 항체 |
| SG10201901057UA (en) | 2014-08-05 | 2019-03-28 | Cb Therapeutics Inc | Anti-pd-l1 antibodies |
| US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| AU2016248376B2 (en) | 2015-04-15 | 2020-10-08 | Beone Medicines I Gmbh | Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
| CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| WO2017044858A2 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| WO2017087851A1 (en) | 2015-11-19 | 2017-05-26 | Genentech, Inc. | Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors |
| WO2018007885A1 (en) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
| CN110087680B (zh) | 2016-08-19 | 2024-03-19 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| IL325835A (en) * | 2016-12-23 | 2026-03-01 | Univ Yale | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES |
| EP3579872A1 (en) | 2017-02-10 | 2019-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
| EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| CA3086765A1 (en) | 2017-12-28 | 2019-07-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| EP3810132A4 (en) | 2018-06-25 | 2022-06-22 | Dana-Farber Cancer Institute, Inc. | TAIRE FAMILY KINASE INHIBITORS AND RELATED USES |
| CN113164477A (zh) | 2018-12-14 | 2021-07-23 | 达纳-法伯癌症研究所股份有限公司 | C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途 |
| EP3902542A4 (en) | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | CYCLIN DEPENDENT KINASE 7 INHIBITORS AND USES THEREOF |
| WO2021041348A1 (en) | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| WO2021120890A1 (en) * | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| AU2021342287A1 (en) | 2020-09-14 | 2023-04-13 | Arvinas Operations, Inc. | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| EP4237412A4 (en) * | 2020-10-30 | 2024-04-10 | Novartis AG | NEW CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR COMPOUND |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| EP4442680A4 (en) * | 2021-11-30 | 2026-05-06 | Abbisko Therapeutics Co Ltd | Pyrazole derivative, its preparation process and its use in medicine |
| WO2024022186A1 (zh) * | 2022-07-29 | 2024-02-01 | 四川科伦博泰生物医药股份有限公司 | 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途 |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1245283A (en) | 1968-10-04 | 1971-09-08 | Labaz | Pyrazole derivatives |
| JP2753659B2 (ja) | 1990-09-03 | 1998-05-20 | 株式会社大塚製薬工場 | ピラゾール誘導体 |
| US5356897A (en) | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| JPH05125079A (ja) | 1991-11-05 | 1993-05-21 | Otsuka Pharmaceut Factory Inc | ピラゾロ［１，５−ａピリミジン誘導体 |
| EP0714898B1 (en) | 1994-06-21 | 2001-11-14 | Otsuka Pharmaceutical Factory, Inc. | PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE |
| US5486534A (en) | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
| US5843951A (en) | 1995-09-28 | 1998-12-01 | Otsuka Pharmaceutical Factory Inc. | Analgesic composition of pyrazolo(1,5-A) pyrimidines |
| JPH10101672A (ja) | 1996-08-06 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | アデノシン増強剤 |
| JPH10101671A (ja) | 1996-08-08 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | 一酸化窒素合成酵素阻害剤 |
| US5932576A (en) | 1997-05-22 | 1999-08-03 | G. D. Searle & Company | 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| JP2000153671A (ja) | 1998-11-20 | 2000-06-06 | Fuji Photo Film Co Ltd | 感熱記録材料 |
| AU4556800A (en) | 1999-04-27 | 2000-11-10 | Smithkline Beecham Plc | Novel treatment |
| TWI271406B (en) | 1999-12-13 | 2007-01-21 | Eisai Co Ltd | Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same |
| JP4739632B2 (ja) | 2000-02-05 | 2011-08-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｅｒｋのインヒビターとして有用なピラゾール組成物 |
| JP4783532B2 (ja) | 2000-02-05 | 2011-09-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｅｒｋのインヒビターとして有用なピラゾール組成物 |
| EP1207864A2 (en) | 2000-02-05 | 2002-05-29 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of erk |
| EP1263753B1 (en) | 2000-03-06 | 2004-05-06 | SmithKline Beecham plc | Imidazol derivatives as raf kinase inhibitors |
| WO2002024680A1 (en) | 2000-09-21 | 2002-03-28 | Smithkline Beecham P.L.C. | Imidazole derivatives as raf kinase inhibitors |
| AU2002226674B2 (en) | 2000-12-28 | 2007-03-22 | Ono Pharmaceutical Co., Ltd. | Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient |
| ES2296910T3 (es) | 2001-01-22 | 2008-05-01 | Sankyo Company, Limited | Compuestos sustituidos con grupo amino biciclicos. |
| WO2002072576A1 (en) * | 2001-03-09 | 2002-09-19 | Pfizer Products Inc. | Benzimidazole anti-inflammatory compounds |
| EP2048142A3 (en) * | 2001-04-26 | 2009-04-22 | Eisai R&D Management Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
| SI1397364T1 (sl) * | 2001-05-24 | 2007-12-31 | Lilly Co Eli | Novi pirolni derivati kot farmacevtske uäśinkovine |
| US6875789B2 (en) | 2001-08-03 | 2005-04-05 | Vertex Pharmaceuticals Incorporated | Pyrazole-derived kinase inhibitors and uses thereof |
| US6750239B2 (en) | 2001-08-03 | 2004-06-15 | Vertex Pharmaceuticals Incorporated | Pyrazole-derived kinase inhibitors and uses thereof |
| GB0121494D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
| GB0121490D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Ciompounds |
| US6897208B2 (en) | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
| US20040010027A1 (en) * | 2001-12-17 | 2004-01-15 | Pharmacia & Upjohn Spa | Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them |
| JP4286146B2 (ja) * | 2001-12-18 | 2009-06-24 | メルク エンド カムパニー インコーポレーテッド | メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤 |
| JP4399265B2 (ja) | 2001-12-21 | 2010-01-13 | ヴァーナリス（ケンブリッジ）リミテッド | ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用 |
| WO2003095455A2 (en) | 2002-05-10 | 2003-11-20 | Smithkline Beecham Corporation | Substituted pyrazolopyrimidines |
| GB0217786D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| EP1539748A1 (en) | 2002-07-31 | 2005-06-15 | Smithkline Beecham Corporation | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
| AU2003256297A1 (en) | 2002-08-09 | 2004-02-25 | Eli Lilly And Company | Benzimidazoles and benzothiazoles as inhibitors of map kinase |
| JP2006501263A (ja) | 2002-09-09 | 2006-01-12 | アムジエン・インコーポレーテツド | 炎症治療用のＴＮＦ−αおよびインターロイキン低下剤としての１，４，５−置換１，２−ジヒドロ−ピラゾール−３−オンおよび３−アルコキシ−１Ｈ−ピラゾール誘導体 |
| WO2004026871A1 (en) * | 2002-09-17 | 2004-04-01 | Eli Lilly And Company | Novel pyrazolopyridine derivatves as pharmaceutical agents |
| WO2004026306A2 (en) | 2002-09-18 | 2004-04-01 | Pfizer Products Inc. | Pyrazole derivatives as transforming growth factor (tgf) inhibitors |
| WO2004026302A1 (en) | 2002-09-19 | 2004-04-01 | Eli Lilly And Company | Methods of inhibiting tgf beta with substituted pyrazoles |
| US7405299B2 (en) * | 2002-11-27 | 2008-07-29 | Eli Lilly And Company | Compounds as pharmaceutical agents |
| US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| CL2004000234A1 (es) | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
| GB0313915D0 (en) * | 2003-06-16 | 2003-07-23 | Smithkline Beecham Corp | Compounds |
-
2006
- 2006-01-27 TW TW095103640A patent/TW200639163A/zh unknown
- 2006-02-02 US US11/345,828 patent/US7491829B2/en not_active Expired - Fee Related
- 2006-02-02 KR KR1020077020119A patent/KR20070107104A/ko not_active Withdrawn
- 2006-02-02 WO PCT/US2006/003654 patent/WO2006084015A2/en not_active Ceased
- 2006-02-02 EP EP06734199A patent/EP1846391A2/en not_active Withdrawn
- 2006-02-02 BR BRPI0607346-8A patent/BRPI0607346A2/pt not_active IP Right Cessation
- 2006-02-02 RU RU2007133111/04A patent/RU2007133111A/ru not_active Application Discontinuation
- 2006-02-02 MX MX2007009405A patent/MX2007009405A/es not_active Application Discontinuation
- 2006-02-02 JP JP2007554205A patent/JP2008530011A/ja active Pending
- 2006-02-02 AU AU2006210626A patent/AU2006210626A1/en not_active Abandoned
- 2006-02-02 CN CNA2006800109351A patent/CN101282960A/zh active Pending
- 2006-02-02 CA CA002596973A patent/CA2596973A1/en not_active Abandoned
- 2006-02-03 AR ARP060100401A patent/AR053014A1/es not_active Application Discontinuation
-
2007
- 2007-08-02 IL IL185024A patent/IL185024A0/en unknown
- 2007-08-17 MA MA30151A patent/MA29310B1/fr unknown
- 2007-08-28 ZA ZA200707289A patent/ZA200707289B/xx unknown
- 2007-09-03 NO NO20074473A patent/NO20074473L/no not_active Application Discontinuation
- 2007-09-04 CR CR9365A patent/CR9365A/es not_active Application Discontinuation
-
2008
- 2008-12-31 US US12/347,412 patent/US20090176809A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007133111A (ru) | Соединения, ингибирующие raf, и способы | |
| US20220251041A1 (en) | 1-cyano-pyrrolidine compounds as usp30 inhibitors | |
| US12202826B2 (en) | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway | |
| US10369153B2 (en) | Pyrrolopyrimidine compounds and uses thereof | |
| AU2001295026B2 (en) | Inhibitors of glycogen synthase kinase 3 | |
| JP4814783B2 (ja) | ピラゾロピリジン誘導体 | |
| TWI583681B (zh) | 胺基嘧啶基化合物 | |
| US7425557B2 (en) | Inhibitors of glycogen synthase kinase 3 | |
| US7037918B2 (en) | Inhibitors of glycogen synthase kinase 3 | |
| US20060063789A1 (en) | Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors | |
| US20220017520A1 (en) | Macrocyclic compound as cdk inhibitor, preparation method therefor, and use thereof in medicine | |
| US20130310395A1 (en) | Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| AU2002363177A1 (en) | Aminobenzamide derivatives as glycogen synthase kinase 3Beta inhibitors | |
| US20140288044A1 (en) | Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors | |
| CN105764514A (zh) | 作为tam族激酶抑制剂的氨基吡啶衍生物 | |
| KR20090125779A (ko) | 브라디키닌 ｂ2 수용체 조절제로서 8-옥시-퀴놀린 유도체 | |
| US20230069174A1 (en) | Nitrogen-containing heterocyclic autotaxin inhibitor, and composition containing same and use thereof | |
| KR20050033660A (ko) | Ｎ-바이아릴메틸 아미노사이클로알칸카복스아미드 유도체 | |
| CA2999935A1 (en) | New imidazo[4,5-b]pyridine derivatives as dual dyrk1/clk1 inhibitors | |
| JP6176244B2 (ja) | 芳香族複素環誘導体及び医薬 | |
| US20220218688A1 (en) | Pyridylpyridone compounds | |
| WO2017068064A1 (en) | Pyridone derivatives and their use as kinase inhibitors | |
| WO2025113806A1 (en) | Thiophene and thiazole derivatives as wip1 inhibitors | |
| HK1138844A (en) | 8-oxy-quinoline derivatives as bradykinin b2 receptor modulators |